Translating Scientific Breakthroughs Into Commercial Success!
At Mireso Consulting, we help biopharma companies launch assets with confidence. From strategy through execution, we provide the specialized expertise that turns breakthroughs into commercial success.
Launch Expertise
We've successfully guided biopharma companies from pre-approval through commercial success, with deep expertise in CGT, oncology, hematology, CNS, and rare conditions.
Execution-Oriented
We don't just deliver recommendations, we provide modular, scalable support that drives execution. Our frameworks are battle-tested and designed for real-world implementation, not theoretical exercises.
Specialized Focus
Unlike generalist consultancies, we specialize exclusively in advanced therapies where complexity demands deep category knowledge and proven frameworks.
Capital Efficiency
Our modular approach ensures you invest resources where they matter most. Scale up or down as your launch needs evolve, from strategic sprints to fractional leadership to full launch PMO support.
BOOK YOUR APPOINTMENT
To cut down on your waiting time, simply book your appointment online.
Our Approach
Strategic Alignment Guaranteed
We begin every engagement by deeply understanding your asset, competitive landscape, organizational capabilities, and launch objectives. Through comprehensive stakeholder interviews, market analysis, and cross-functional assessments, we identify the critical opportunities and risks that will shape your commercial success.
Our discovery phase ensures alignment across your entire organization—from R&D to commercial—so everyone is working toward the same launch goals with clarity and confidence.
What You Get:
- Comprehensive launch readiness assessment
- Competitive landscape analysis
- Stakeholder alignment sessions
- Risk identification and mitigation planning
- Clear strategic roadmap
Tailored Launch Strategy
Drawing on 20+ years of biopharma expertise and 10+ successful launches, we develop commercial strategies specifically designed for the complexity of advanced therapies. Unlike generic frameworks, our approach accounts for the unique challenges of cell & gene therapy and rare disease, from payer scrutiny to patient identification.
We work collaboratively with your team to create actionable strategies that balance scientific innovation with commercial reality, ensuring your breakthrough therapy achieves the market impact it deserves.
What You Get:
- Go-to-market strategy and launch sequencing
- Value proposition and competitive positioning
- Pricing and market access strategy
- KOL engagement and medical affairs planning
- Commercial model and resource requirements
Implementation Excellence
Strategy without execution is just a PowerPoint deck. We translate strategic recommendations into detailed execution plans with clear timelines, owners, and success metrics. Our modular Launch PMO approach provides flexible support across market access, medical affairs, commercial operations, and patient engagement.
Whether you need end-to-end orchestration or targeted support for specific functions, we ensure seamless coordination across your organization to eliminate silos and accelerate launch readiness.
What You Get:
- Detailed implementation roadmap
- Cross-functional coordination and governance
- Launch PMO support (modular or comprehensive)
- Milestone tracking and accountability
- Real-time problem solving and course correction
Continuous Performance Enhancement
Launch day is just the beginning. We provide ongoing support to monitor performance, identify emerging challenges, and optimize tactics based on real-world results. As market dynamics evolve and competitive landscapes shift, we help you adapt quickly to maintain momentum and maximize commercial outcomes.
Our data-driven approach ensures you're making informed decisions that drive sustained growth, from refining messaging to adjusting channel strategies to expanding into new markets.
What You Get:
- Performance monitoring and analytics
- Launch metrics tracking and reporting
- Strategic adjustments based on market feedback
- Competitive intelligence updates
- Expansion planning and market sequencing
Measurable Commercial Success
Our ultimate measure of success is your commercial performance. Across 10+ launches, we've helped clients exceed KPIs, accelerate time-to-adoption, secure favorable reimbursement, and build sustainable market leadership in advanced therapies.
From faster payer approvals to stronger physician advocacy to improved patient access, we deliver tangible results that drive both near-term revenue and long-term enterprise value.
Proven Outcomes:
✓ Launches exceeding revenue forecasts and KPIs
✓ Accelerated time-to-reimbursement and market access
✓ Stronger KOL engagement and scientific credibility
✓ Improved patient identification and treatment uptake
✓ Enhanced board and investor confidence
✓ Successful BD partnerships and licensing deals
FLEXIBLE ENGAGEMENT MODELS
Project-Based Strategy
Perfect for early-stage biotech preparing for first-in-human or pivotal trials, or larger firms needing a sprint team for critical gaps in your launch planning.
What's included:
- Focused strategic consulting
- Specific deliverable (opinion leader strategy, launch readiness assessment, or competitive positioning)
- Expert analysis and actionable recommendations
- Executive presentation and handoff
Modular Launch PMO
If you have late-stage assets and lean teams, this is the package for you. Comprehensive support across market access, medical affairs, commercial, and patient engagement—modular and flexible.
What's Included:
- End-to-end launch orchestration
- Cross-functional PMO governance
- Market access, medical affairs, commercial, and patient engagement modules
- Ongoing strategic guidance and execution support
- Performance tracking and optimization
- Fractional leadership access
Fractional Leadership
Our most comprehensive package, perfect for mid-sized biopharma with strong R&D but limited commercial bench strength.
What's Included:
- Embedded fractional CCO support
- Strategic planning and execution oversight
- Board-level reporting and investor relations support
- Team development and capability building
- Advisory board participation
- Full access to Mireso's network and expertise
- Ongoing optimization through launch and beyond
Meet Michelle Sobers, MBA
Founder & Managing PARTNER
With over 20 years of experience across Eli Lilly, Allergan, Janssen, Agios, and Servier, our founder brings a rare combination of scientific rigor and strategic insight to every project. As a former Director at Kite Pharma, she co-led the successful opinion leader strategy for the second line launch of Yescarta CAR-T, one of the most transformative innovations in cancer therapy.
Previously a hematology and oncology research scientist at UPMC, she bridges deep scientific expertise with real-world commercialization strategy, ensuring that breakthrough research translates into meaningful patient outcomes.
She holds a BS in Biology (Genetics) from Carnegie Mellon University and an MBA from George Washington University, embodying a lifelong commitment to driving innovation from bench to business and from research to real-world impact.
Why Choose Mireso CONSULTING?
01
Accelerate Your Launch Success
Proven frameworks from 10+ successful launches ensure you reach market faster and achieve commercial objectives from Day 1.
02
Specialized CGT & Rare Disease Expertise
Extensive experience in cell therapy and rare disease—no generic consulting, just real world strategies for advanced therapies.
03
From Strategy to Execution
Hands-on implementation support that scales with your needs, ensuring seamless execution throughout your launch journey.
04
Capital Efficient & Flexible
Modular engagement models that scale up or down as needed—invest resources exactly where they matter most.
Ready to De-Risk Your Advanced Therapy Launch?
Whether you're preparing for a launch or scaling an advanced therapy portfolio, we're here to help you achieve success. Schedule a free 30-minute consultation now!
